FHIR IG analytics| Package | hl7.fhir.uv.xver-r2.r4b |
| Resource Type | ValueSet |
| Id | ValueSet-R2-v3-substanceAdminSubstitution-for-R4B.json |
| FHIR Version | R4B |
| Source | http://hl7.org/fhir/xver-r2.r4b/0.0.1-snapshot-2/ValueSet-R2-v3-substanceAdminSubstitution-for-R4B.html |
| URL | http://hl7.org/fhir/1.0/ValueSet/R2-v3-substanceAdminSubstitution-for-R4B |
| Version | 0.0.1-snapshot-2 |
| Status | active |
| Date | 2025-09-01T22:35:43.086706+10:00 |
| Name | R2_v3_substanceAdminSubstitution_for_R4B |
| Title | Cross-version VS for R2.v3 Code System substanceAdminSubstitution for use in FHIR R4B |
| Realm | uv |
| Authority | hl7 |
| Description | This cross-version ValueSet represents concepts from http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31 for use in FHIR R4B. Concepts not present here have direct `equivalent` mappings crossing all versions from R2 to R4B. |
No resources found
| CodeSystem | |
| substanceAdminSubstitution | v3-substanceAdminSubstitution |
Note: links and images are rebased to the (stated) source
Generated Narrative: ValueSet R2-v3-substanceAdminSubstitution-for-R4B
This value set expansion contains 9 concepts.
| Code | System | Display | Definition |
| BC | http://hl7.org/fhir/v3/substanceAdminSubstitution | brand composition | Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven |
| G | http://hl7.org/fhir/v3/substanceAdminSubstitution | generic composition | Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) |
| EC | http://hl7.org/fhir/v3/substanceAdminSubstitution | equivalent composition | Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril |
| TB | http://hl7.org/fhir/v3/substanceAdminSubstitution | therapeutic brand | Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet |
| TG | http://hl7.org/fhir/v3/substanceAdminSubstitution | therapeutic generic | Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine |
| TE | http://hl7.org/fhir/v3/substanceAdminSubstitution | therapeutic alternative | Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet |
| E | http://hl7.org/fhir/v3/substanceAdminSubstitution | equivalent | Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. |
| F | http://hl7.org/fhir/v3/substanceAdminSubstitution | formulary | Description: This substitution was performed or is permitted based on formulary guidelines. |
| N | http://hl7.org/fhir/v3/substanceAdminSubstitution | none | No substitution occurred or is permitted. |
FHIR
FHIRsmith{
"resourceType": "ValueSet",
"id": "R2-v3-substanceAdminSubstitution-for-R4B",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode": "fhir"
},
{
"extension": [
{
"url": "packageId",
"valueId": "hl7.fhir.uv.xver-r2.r4b"
},
{
"url": "version",
"valueString": "0.0.1-snapshot-2"
}
],
"url": "http://hl7.org/fhir/StructureDefinition/package-source"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
"valueInteger": 0,
"_valueInteger": {
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
"valueCanonical": "http://hl7.org/fhir/1.0/ImplementationGuide/hl7.fhir.uv.xver-r2.r4b"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
"valueCode": "trial-use",
"_valueCode": {
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
"valueCanonical": "http://hl7.org/fhir/1.0/ImplementationGuide/hl7.fhir.uv.xver-r2.r4b"
}
]
}
}
],
"url": "http://hl7.org/fhir/1.0/ValueSet/R2-v3-substanceAdminSubstitution-for-R4B",
"version": "0.0.1-snapshot-2",
"name": "R2_v3_substanceAdminSubstitution_for_R4B",
"title": "Cross-version VS for R2.v3 Code System substanceAdminSubstitution for use in FHIR R4B",
"status": "active",
"experimental": false,
"date": "2025-09-01T22:35:43.086706+10:00",
"publisher": "FHIR Infrastructure",
"contact": [
{
"name": "FHIR Infrastructure",
"telecom": [
{
"system": "url",
"value": "http://www.hl7.org/Special/committees/fiwg"
}
]
}
],
"description": "This cross-version ValueSet represents concepts from http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31 for use in FHIR R4B. Concepts not present here have direct `equivalent` mappings crossing all versions from R2 to R4B.",
"jurisdiction": [
{
"coding": [
{
"system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code": "001",
"display": "World"
}
]
}
],
"compose": {
"include": [
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"concept": [
{
"code": "BC",
"display": "brand composition"
},
{
"code": "G",
"display": "generic composition"
},
{
"code": "EC",
"display": "equivalent composition"
},
{
"code": "TB",
"display": "therapeutic brand"
},
{
"code": "TG",
"display": "therapeutic generic"
},
{
"code": "TE",
"display": "therapeutic alternative"
},
{
"code": "E",
"display": "equivalent"
},
{
"code": "F",
"display": "formulary"
},
{
"code": "N",
"display": "none"
}
]
}
]
},
"expansion": {
"timestamp": "2025-09-01T22:35:43.086701+10:00",
"contains": [
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "BC",
"display": "brand composition"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "G",
"display": "generic composition"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "EC",
"display": "equivalent composition"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "TB",
"display": "therapeutic brand"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "TG",
"display": "therapeutic generic"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "TE",
"display": "therapeutic alternative"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "E",
"display": "equivalent"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "F",
"display": "formulary"
},
{
"system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
"version": "1.0.2",
"code": "N",
"display": "none"
}
]
}
}